Clinical response in metastatic castration‐resistant prostate cancer (mCRPC) cases treated with supra‐physiological doses of testosterone: Bipolar androgen therapy

Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoshi, Senji, Bilim, Vladimir, Hoshi, Kiyotsugu, Nakagawa, Takuya, Sato, Sadanobu, Sakagami, Rie, Konno, Masato, Kudo, Takashi, Numahata, Kenji, Sasagawa, Isoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829667/
https://www.ncbi.nlm.nih.gov/pubmed/35154735
http://dx.doi.org/10.1002/ccr3.5433
Descripción
Sumario:Androgen deprivation therapy is a standard of care for metastatic prostate cancer. A paradoxical approach utilizing high doses of testosterone in castration‐resistant prostate cancer patients demonstrated clinical responses. Here, we report on four heavily pretreated Japanese patients (including one patient on hemodialysis) successfully treated with supra‐physiological doses of testosterone.

Ejemplares similares